Movement Alert｜PHARMARON Intraday Rise 4.76% in Regular Trading, JPMorgan Increased Its H-Share Stake

Market Focus14:21

On October 23, PHARMARON rose 4.76% in Regular Trading, trading at HK$27.3, with turnover of HK$91.42 million.

The clearest catalyst in public disclosures was a new H-share position increase by JPMorgan. Exchange data showed JPMorgan added about 460,100 shares on October 16 at an average price of about HK$26.16 per share, involving roughly HK$12.04 million. After the increase, its latest holding rose to about 57.90 million shares, or 16.08% of the company’s H shares.

The move also coincided with a broader rebound in Life Sciences Tools & Services names. On the same day, WUXI BIO rose 2.74%, WUXI XDC rose 3.77%, WUXI APPTEC rose 0.38%, and INSILICO rose 1.17%, while GENSCRIPT B-1K fell 2.55%.

PHARMARON is a China-based pharmaceutical R&D services company spanning laboratory services, chemistry and manufacturing services, clinical research, and biologics as well as cell and gene therapy. The company is scheduled to review its third-quarter results on October 27, keeping near-term attention on fundamentals alongside shareholding changes.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment